Cohance Lifesciences to Hold 7th AGM on Sep 19, 2025; Annual Report for FY25 Available
The announcement concerns a routine Annual General Meeting and the dissemination of the annual report, which are standard corporate governance activities and regulatory compliance. It does not indicate any material changes to the company's business operations, financial performance, or strategic direction.
The announcement is a standard disclosure about an upcoming AGM and the availability of the annual report, along with routine shareholder compliance reminders. It does not contain information that would directly impact the company's financial performance or outlook.
* Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its 7th Annual General Meeting (AGM) is scheduled for Friday, September 19, 2025, at 2:30 p.m. (IST). * The AGM will be conducted through Video Conference (VC) / Other Audio-Visual Means (OAVM). * The Notice of the 7th AGM along with the Annual Report for the financial year 2024-25 is being sent electronically to members with registered email IDs. * For shareholders whose email IDs are not registered, the company is providing a weblink to access the Annual Report for FY 2024-25 on its website: `https://www.suvenpharm.com/pdf/Investors/Financial-Info/Cohance_AnnualReport_2025.pdf`. * Shareholders are advised to update their PAN, KYC details (including postal address, email, mobile number, bank account details), and nomination details, as per SEBI guidelines. Payments, including dividends, for folios with unupdated PAN or KYC will only be made electronically upon registration of the required information. * A Senior Citizens Investor Cell has been formed by the RTA (KFintech) to assist shareholders above 60 years of age with grievances, complaints, and queries. Senior citizens can contact senior.citizen@kfintech.com or call the toll-free number 1800 3094 006.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.